T cells

[International Immunopharmacology] Personalized immunotherapy has recently been proposed as a potential complementary medicine with immunotherapy and chemotherapy for overcoming breast cancer (BC). Scientists discuss the brief association of these methods and future directions in BC immunotherapy.

[ImmunityBio, Inc.] ImmunityBio, Inc. announced it has received FDA authorization to conduct a Phase Ib/II open-label study to evaluate the safety and preliminary efficacy of its superagonist Anktiva and PD-L1 targeted high-affinity natural killer (t-haNK) cells in combination with standard chemo and Trodelvy, in subjects with advanced TNBC.

[Cancer Gene Therapy] Scientists made a comprehensive review on the outcomes resulted from the combination of CAR T-cell immunotherapy and oncolytic virotherapy for the treatment of solid cancers.

[Cancer Gene Therapy] A highly acidified microenvironment of melanoma induced the expression of G-protein-coupled receptor in T cells, which weakened their effective function and promote tumor growth.

[Diabetes] Using a transcriptome-wide profiling approach to map translation initiation start sites in human beta-cells under standard and inflammatory conditions, researchers identified a completely new set of polypeptides derived from non-canonical start sites and translation initiation within lncRNA.

[Chemico-Biological interactions] The effects of prodrug 1 were studied in lipopolysaccharide-induced in vitro and in vivo apoptosis and pancreatitis models by determining the cellular apoptotic levels with human umbilical vein endothelial cells and pancreatic caspase-3/-7 activity in mice.